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Introduction
The incidence of HIV-1 infection is increasing among
women in Taiwan and worldwide. Most infections oc-
cur through heterosexual transmission [1]. Emerging
data show that some aspects of HIV disease may dif-
fer between men and women [2,3]. A knowledge of
sex-specific differences may elucidate important deter-
minants of risk of heterosexual and perinatal trans-
mission, increase our understanding of HIV-1 patho-
genesis, help in the analysis of therapeutic effects and
design of prevention strategies, and enhance our under-
standing of the factors that influence disease progression
in women, including the potential role of sex hormones.
Recent studies found that, for a given CD4 cell
count, women had plasma HIV-1 RNA levels approxi-
mately 30–50% lower than those in men [3]. Several
lines of evidence suggest that hormonal variations
through the menstrual cycle could have an impact on
viral dynamics in the female genital tract. However, two
recent publications have reported contradictory re-
sults about the effect of sex hormones on HIV-1 virus
burden [4,5]. Although the biological basis for sex-
related differences in HIV infection is most likely to be
hormonal, little is known about the effects of endogen-
ous and exogenous sex hormones on the course of
HIV infection. Few studies have attempted to address
the issue of potential variation of peripheral blood and
genital tract viral load through the menstrual cycle [6–
8]. It is unclear whether hormonal changes during the
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menstrual cycle affect immunologic markers in HIV-
infected women. The objectives of this study were to
determine whether the lymphocyte subsets and their
immunologic markers change during the follicular and
luteal phases and to further discuss the effect of sex
hormones on the disease course of HIV-seropositive
women.
Methods
Participants
Between October 1997 and 2001, the study enrolled 21
HIV-infected women, all of whom had enzyme-linked
immunosorbent assay and Western immunoblotting
evidence of HIV infection, and 30 matched controls.
All subjects were over 18 years of age, not pregnant,
and had regular menstrual cycles (25–30-day interval,
variation smaller than 3 days) during the preceding 6
months. Women were excluded if they had received a
vaccination, narcotics, estrogens, progestins, or anti-
retroviral medications. Participants were recruited at
National Taiwan University Hospital and followed dur-
ing a routine, monthly visit by the same investigator
(HNH). At least six blood samples were collected from
each patient.
Study design
Historical and physical data were obtained by trained
interviewers and research clinicians. Participants were
asked to contact project staff within 3 days of the onset
of menstrual bleeding and were then scheduled for
studies in the menstrual period, follicular and luteal
phases. Weight, height, body mass index, medications,
menstrual history, smoking status, and confirmation
of the presence of serum HIV antibody were recorded.
Medical history was updated (dates of onset of men-
struation, new medications, use of illicit drugs, and
acute illnesses). A detailed pelvic examination, at which
cervical and vaginal secretions and exfoliated cells were
collected for another study, and phlebotomy were
performed at each visit.
Laboratory methods
Because serial ovarian ultrasonography and daily
serum sampling were not performed, menstrual phase
was determined by careful review of menstrual history
and endocrine analyses of blood samples. Peripheral
blood was collected between 7:30 and 9:30 AM by
venipuncture into glass collection tubes. Serum was
separated and frozen for batch testing. Serum con-
centrations of follicle-stimulating hormone, luteini-
zing hormone, estradiol, and progesterone were
quantified in duplicate using the IMMULITE immuno-
assay system (Diagnostic Products Corporation, Los
Angeles, CA, USA) with inter- and intra-assay coef-
ficients of variation of less than 11% and less than
8%, respectively. Peripheral blood mononuclear cells
(PBMCs) were separated by Ficoll-Paque gradient cen-
trifugation and resuspended in a solution containing
90% RPMI -1640 and 10% heat-inactivated fetal calf
serum (FCS).
T-cell analyses focused on CD4+ lymphocytes be-
cause these cells, which are essential for the initiation of
cell-mediated immune responses, are the primary in vivo
targets for HIV-1, and their depletion is one of the most
important aspects of the pathogenesis of AIDS. CD8+
lymphocytes were also studied because they are the
other major class of circulating T cells and because they
have been reported to kill target cells infected with HIV-
1 and to suppress HIV-1 replication in vitro.
For cell-surface staining, 1 × 106 PBMCs were incu-
bated with various monoclonal antibodies (Becton
Dickinson Bioscience, San Jose, CA, USA) at 4°C for
30 minutes, followed by washing with staining buffer
(phosphate-buffered saline, PBS/FCS/azide). Three-
color surface staining was used to assess the expres-
sion of different activation markers (HLA-DR, CD38,
CD69, and CD25) on lymphocyte subsets. A gate was
set around the lymphocytes (CD45+CD14–) to exclude
other cells from analysis. The monoclonal antibodies
anti-CD3, anti-CD19 and anti-CD16+CD56 were used
to analyze T cells, B cells, and natural killer (NK) cells,
respectively, in the population of lymphocytes. These
activation markers were stained with fluorescein iso-
thiocyanate-conjugated mouse immunoglobulin G
(IgG) monoclonal antibodies and CD4 and CD8 were
stained with mouse anti-human PE (phycoerythrin)
conjugated monoclonal antibodies. In addition, cells
were stained for CD3 with peridinin chlorophyll protein-
conjugated monoclonal antibodies. Nonspecific isotype-
matched monoclonal antibodies (IgG2a/IgG1) were
used as controls. Flow cytometric analyses were
performed using a FACScan cytofluorimeter (Becton
Dickinson) with computer interfacing to CellQuest soft-
ware (Bccton Dickinson) for full list mode data storage,
recovery, and analysis.
Results
Fewer CD4+ lymphocytes and more CD8+ lymphocytes
in HIV-positive women
There was a broad range of values for both CD4+ and
CD8+ lymphocytes in both normal and seropositive
individuals (Table 1). Absolute numbers and percent-
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ages of T-cell subsets showed the same trends. Sero-
positive women had substantially lower CD4+ cell counts
and higher CD8+ cell counts than controls. However,
the CD3 (CD4 + CD8, total T) cell counts remained
constant.
No difference in percentages of lymphocyte subsets in
both phases
There was no difference in the percentage of various
lymphocyte subsets between HIV-positive and normal
women in either the follicular or luteal phase (Table 2).
CD8+ cell counts were increased in the luteal phase
compared with the follicular phase in normal women.
However, this increase disappeared in HIV-positive
women. HIV infection led to an increase in CD8+ cells
during the follicular phase of the menstrual cycle.
Increased activation (HLA-DR and CD38) of CD8+
T cells in HIV-positive women
An increase in expression of the activation markers
HLA-DR and CD38 was seen exclusively on CD8+ cells of
HIV-positive women compared with controls (Table 3).
There were no changes in CD25 and CD69 expression
on either CD4+ or CD8+ cells.
Discussion
AIDS was first reported in the USA in 1981 [9], and its
association with HIV infection was shown in 1983 [10].
HIV-1 infection results in depletion of CD4+ T cells,
elevation of CD8+ T cells, and progressive impairment
of immune function. HIV-1 has selective tropism for
the CD4 molecule that is mainly on the surface of
helper T lymphocytes, causing both quantitative and
qualitative defects in CD4+ T lymphocytes through
multiple mechanisms. Absolute CD4+ cell count is most
commonly used to describe the status of HIV disease
in an individual and is one of the most important pre-
dictors of disease progression to AIDS in HIV-infected
patients. In most HIV-infected persons, the CD4+ count
falls by 0.02–0.1 × 109/L/year [11]. The 3-year pro-
gression rate to AIDS in a cohort of homosexual men
Table 1. Absolute numbers of T-cell subsets in HIV-
positive women and normal controls
Absolute number of cells/mm3
CD4+ CD8+
Normal (n = 30) 1,084 ± 485, 610 ± 203
HIV-positive (n = 21) 0406 ± 212 953 ± 407
Mean ± standard deviation.
Table 2. Percentage of various lymphocytes in HIV-positive and normal women during follicular and luteal phases
HIV-positive Normal control
Follicular Luteal Follicular Luteal
B cells 14.1% ± 4.0% 13.6% ± 5.4% 14.4% ± 5.6% 15.7% ± 6.4%
T cells 64.3% ± 8.9% 65.4% ± 7.4% 70.2% ± 7.6% 71.8% ± 7.5%
CD8+ cells 044.8% ± 13.7% 048.4% ± 10.4% 0.26.4% ± 7.6%* 43.5% ± 4.7%
NK cells 17.5% ± 7.5% 17.6% ± 8.2% 12.0% ± 8.3% 12.4% ± 7.3%
Mean ± standard deviation. *p < 0.05 vs luteal phase. NK = natural killer.
Table 3. Activation status of CD8+ and CD4+ T cells during follicular and luteal phases
HIV-positive Normal control
Follicular Luteal Follicular Luteal
CD8 (CD3+CD8+)
HLA-DR+/CD8+ 35.5% ± 6.4%* 37.3% ± 5.5%* 7.8% ± 9.8% 8.1% ± 9.0%
CD38+/CD8+ 45.1% ± 8.2%* 44.8% ± 7.7%* 8.9% ± 5.7% 9.1% ± 7.9%
CD69+/CD8+ 11.4% ± 7.7%0 9.4% ± 4.8% 7.2% ± 6.3% 8.1% ± 6.6%
CD25+/CD8+ 5.4% ± 3.6% 3.8% ± 2.4% 3.0% ± 6.1% 2.2% ± 2.8%
CD4 (CD3+CD4+)
HLA-DR+/CD4+ 15.0% ± 7.6%0 13.2% ± 5.9%00 9.7% ± 4.7% 9.8% ± 5.0%
CD38+/CD4+ 8.4% ± 7.3% 10.1% ± 6.4%00 9.7% ± 7.2% 9.4% ± 6.4%
CD69+/CD4+ 8.6% ± 5.0% 9.2% ± 4.6% 6.1% ± 8.9% 8.2% ± 8.2%
CD25+/CD4+ 20.6% ± 14.6% 16.7% ± 7.2%0 14.9% ± 5.5%0 13.9% ± 4.8%0
Mean ± standard deviation. *p < 0.05 vs normal women by Mann-Whitney U test.
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in San Francisco who were seropositive for HIV was
87%, 46%, and 16% for patients with CD4+ counts of
0–200, 201–400, and more than 400 cells/mm3,
respectively [11]. Our HIV-seropositive women were
mostly in early asymptomatic HIV disease (>200 CD4+
cells/mm3).
In Taiwan, HIV infection is still rare. There were
6,552 cases reported by the Center for Disease Control
up to November 2004, of which only 444 cases were
female. Early studies suggested that HIV-infected women
may progress to AIDS and death faster than men [12].
However, some studies have reported similar rates of
CD4+ cell decline and time to AIDS between men and
women [13], and there is no gender difference in HIV-
1 RNA levels [4,5]. Nevertheless, these reports may
have been limited by small sample size and by a failure
to match fully for CD4+ cell counts. Recent data have
suggested that HIV-1 RNA viral load measures are 38–
65% lower in women than in men with a similar CD4+
count, which implies that at the same viral load, women
have a higher risk of AIDS [3]. Anastos et al found that
CD4+ cell decline was more rapid in women [14]. This
more rapid decline suggests that clinical disease
progression may be more rapid in women [3]. Many
investigators have proposed that the different hormo-
nal status of women and men has an effect on viral
dynamics. Studies of HIV-uninfected persons indicate
that women have significantly higher CD4+ cell percent-
ages and counts than men [15]. Reproductive hormones
are known to have effects on lymphocyte function and
cytokine production [16]. Tumor necrosis factor-_,
which is associated with immune activation and in-
creased viral replication, may be inhibited by estrogen,
resulting in lower viral load [17]. Thus, based on the
currently available data, there is a sex difference in the
natural course of HIV disease, and the guidelines for
the use of antiretroviral therapy in HIV-1 infection may
be revised for women.
There are very few data on the effects of sex steroids
on the progression of HIV infection, and no firm con-
clusions can be drawn. A simian model demonstrated
an increase in plasma viral RNA levels after progesterone
was implanted in seropositive macaques [18]. How-
ever, a study of HIV-infected women over 40 years of age
demonstrated that the use of hormone replacement
therapy was associated with an improved survival rate
[19]. Nevertheless, when controlling for CD4+ cell count,
use of antiretroviral therapy, and a history of AIDS-
defining illnesses, hormonal contraceptive use was not
associated with viral load changes over time, regardless
of the type of oral contraceptive used [20]. Further-
more, several large studies of HIV infection in pregnancy
have suggested no influence of gestation on disease
progression [21,22]. Therefore, the use of hormonal
contraception and the hormonal changes during preg-
nancy seem to have no effect on the course of HIV-1
disease.
Studies have shown that the length of the menstru-
al cycle and the duration of menstrual bleeding are
not significantly different between HIV-infected and
-uninfected women, which suggests that most HIV-
infected women ovulate monthly and have an intact
hypothalamic-pituitary-ovarian axis [23]. Recent studies
have shown that the amount of HIV-1 RNA in vaginal
secretions is strongly correlated with that in plasma
[24]. Several studies have examined mucosal virus
levels at different times during the menstrual cycle in
order to evaluate the influence of endogenous hormones
on virus shedding [6–8]. These studies have generated
variable results with evidence both for and against an
impact of endogenous hormones on genital levels of
virus. However, most studies demonstrated that plas-
ma HIV-1 RNA levels did not change significantly from
week to week during the menstrual cycle [6,8]. This
suggests that plasma estradiol and progesterone levels
are not correlated with plasma virus load. Therefore,
our results provide further evidence that hormonal
changes during the menstrual cycle do not affect the
immune cells in blood. Nevertheless, HIV infection
changes the T-cell subsets and makes the differences
across menstrual phases disappear.
Although the cytopathic effects of HIV on T cells in
vitro have been well described, the “direct killing”
hypothesis cannot account for all the complexities of
the disease and indirect effects of HIV infection, primarily
the wide and chronic immune activation of the host that
it causes, and may better account for the main changes
observed during HIV progression and AIDS [25]. There-
fore, assessment of immune activation during follow-
up of patients, especially after antiretroviral therapy,
might be a more meaningful outcome measure of
treatment success than measurement of viral load
and CD4+ cell counts alone [26]. HIV-1 infection causes
activation of B and T cells, which consequently up-
regulates the surface expression of CD38 and other
activation markers, such as HLA-DR, as shown in our
previous study [27] and this study. CD38 expression
in CD8+ cells is upregulated at seroconversion and is
maintained at high levels in those who are short pro-
gressors or decreases in subjects with stable CD4+ cell
counts [28]. Because high proportions of CD8+CD38+
T cells predict progression in HIV-1-infected adults,
the high CD38 expression on CD8+ T cells is a marker of
poor prognosis. In our patients, lymphocyte activation
with increased CD38 expression is detrimental since
this activation favors cell infection by upregulating
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molecules involved in HIV-1 replication [29]. However,
the expression of early activation markers, CD69 and
CD25, was not significantly changed on T cells from
seropositive patients. The rapid expression of these
activation antigens after mitogenic stimulation was
used to evaluate the proliferative functionality of lym-
phocytes [30]. Because HIV infection itself impairs
the propagation of T lymphocytes, the expression of
CD69 and CD25 was not increased in these patients.
In the present study, we found that hormonal changes
during the menstrual cycle did not have a significant
effect on the distribution of systemic immune cells. The
controversy about the potential role of sex hormones on
the genital tract viral load may be due to local
nonmenstrual factors, such as fluctuations in cytokine
and chemokine concentrations and cytotoxic T-cell
activity in the genital tract. Additional research is needed
to identify these influencing factors and apply the
knowledge to prevent the transmission of HIV-1
infection.
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